血脂康治疗2型糖尿病合并高脂血症临床随机对照试验的Meta分析*

目的：运用Meta分析评价血脂康对2型糖尿病合并高脂血症患者的临床疗效。方法：检索Pubmed、Web of Knowledge、The Cochrane library、中国学术期刊数据库(China National Knowledge Infrastructure, CNKI)、维普中文科技期刊数据库(Chinese Scientifc Journal Database, VIP)、万方数据库中的文献，检索年限为2000年1月—2019年9月，筛选所有血脂康治疗2型糖尿病合并高脂血症临床随机对照试验(randomized controlled trial, RCT)。应用改良Jadad评分法进行质量评价，应用RevMan 5.2软件进行Meta分析。结果：共纳入13个RCT，均为低质量研究。血脂康试验组总胆固醇、三酰甘油、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、空腹血糖，餐后2 h血糖及糖化血红蛋白等指标的改善均较常规治疗对照组明显(P<0.05)。结论：在常规降糖治疗基础上加用血脂康对于改善2型糖尿病合并高脂血症患者的血脂及血糖均优于常规降糖治疗。

Effect of Xuezhikang on type 2 diabetes mellitus with hyperlipemia: a Meta-analysis of randomized controlled trials

Objective: To evaluate the clinical therapeutic effect of Xuezhikang on type 2 diabetes mellitus with hyperlipemia by Meta-analysis. Methods: The documents were searched in the data bases including Pubmed, Web of Knowledge, The Cochrane Library, China National Knowledge Infrastructure(CNKI), Chinese Scientifc Journal Database(VIP) and Wanfang Database within the retrieval period from January 2000 to September 2019. Then random control trial(RCT) studies on Xuezhikang treatment for type 2 diabetes mellitus with hyperlipemia were selected, and their qualities were estimated by improved Jadad score method. Finally, the software RevMan 5.2 was used for the meta-analysis. Results: Thirteen RCT studies were included in this study and estimated as low quality. Meta-analysis showed that the improvement effects on total cholesterol, triglycerides, low density lipoprotein-cholesterol, high density lipoprotein-cholesterol, fasting blood-glucose, 2 h postprandial blood-glucose and glycosylated hemoglobin Alc after treatment in Xuezhikang group were better than control group with statistic significance(P<0.05). Conclusion: The therapeutic effect on blood lipid and blood glucose in routine glycemic control combined with Xuezhikang was superior to routine glycemic control alone in the treatment of type 2 diabetes with hyperlipemia.